3D Printed Drugs Market by Spritam (U.S. and Rest of World) and Other Drugs Potential Market by Scenario (Rapid Growth Scenario, Moderate Growth Scenario, and Low Growth Scenario) - Global Opportunity Analysis and Industry Forecast, 2017-2030

November 2017 | 125 pages | ID: 3024366D32EEN
Allied Market Research

Abstracts

Spritam is the only 3D printed drug which has received FDA approval. This drug was first available in the market in 2016, and can be used to treat epilepsy. The potential market for other 3D printed drugs (moderate growth scenario) is estimated to be $278 million in 2020, and would reach $522 million by 2030, growing at a CAGR of 6.5% from 2020 to 2030. 3D printed drugs are developed by 3D printing technology to treat patients and children affected with dysphagia. These drugs are highly porous in nature and disintegrate rapidly, which eliminate the need to directly swallow the intact high-dose medicine.
The growth of the 3D printed drugs market is driven by upsurge in demand of instantaneous soluble drugs, rise in geriatric population, and high adoption of 3D printing technology. In addition, rapid technological advancements, increase in awareness about the 3D printing, and improvement in healthcare infrastructure fuel the market growth. However, factors such as adverse effects related to these drugs, lack of government regulations for these drugs, and use of 3D printing to develop illegal drugs are expected to restrain the market growth. Conversely, introduction of 3D printed drugs by various key vendors in developing nations and increase in healthcare investment in emerging nations are expected to provide lucrative opportunities for the market growth in the near future.

The market is segmented on the basis of Spritam, scenario, and geography. For Spritam, market is categorized on the basis of geography into U.S. and rest of North America. On the basis of scenario, the market is categorized into low growth scenario, moderate growth scenario, and rapid growth scenario. Geographically, it is analyzed across North America (U.S. and rest of North America), Europe (UK, Germany, France, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, Australia, and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, and rest of LAMEA).

KEY BENEFITS FOR STAKEHOLDERS

• The study provides an in-depth analysis of the global 3D printed drugs market with current trends and future estimations to elucidate the investment pockets.
• Comprehensive analysis of factors that drive and restrict the growth of the market is provided.
• The report offers a quantitative analysis to assist the stakeholders to capitalize on prevailing market opportunities.
• Extensive analysis of different segments facilitates to determine various products available in the market.
• Key players are profiled and their strategies are analyzed thoroughly to predict the competitive market outlook.

SPRITAM MARKET, BY GEOGRAPHY

• U.S.
• Rest of World

OTHER DRUGS POTENTIAL MARKET, BY SCENARIO

• Low Growth Scenario
• Moderate Growth Scenario
• Rapid Growth Scenario

OTHER DRUGS POTENTIAL MARKET, BY REGION

• North America
• U.S.
• Rest of North America
• Europe
• UK
• Germany
• France
• Italy
• Spain
• Rest of Europe
• Asia-Pacific
• Japan
• China
• Australia
• Rest of Asia-Pacific
• LAMEA
• Brazil
• Saudi Arabia
• Rest of LAMEA

LIST OF KEY PLAYERS PROFILED IN THE REPORT

• Aprecia Pharmaceuticals
• GlaxoSmithKline Plc.
• Hewlett Packard Caribe, BV, LLC
• 3D Printer Drug Machine
• FabRx Ltd.

LIST OF ORGANIZATIONS PROFILED IN THE REPORT

• UCL School of Pharmacy
• University of Glasgow
• University College London
• The University of Nottingham
• National University of Singapore

LIST OF OTHER ORGANIZATIONS IN THE VALUE CHAIN (These players are not profiled in the report, but can be included on client request.)

• University of Michigan
• ?bo Akademi University
• University of Sheffield

Contents

CHAPTER 1 INTRODUCTION

1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS FOR STAKEHOLDERS
1.3. KEY MARKET SEGMENTS

CHAPTER 2 EXECUTIVE SUMMARY

2.1. KEY FINDINGS OF THE STUDY
2.2. CXO PERSPECTIVE

CHAPTER 3 MARKET OVERVIEW

3.1. MARKET DEFINITION AND SCOPE
3.2. 3D PRINTED DRUGS: AN OVERVIEW
  3.2.1. Why 3D printed drugs?
  3.2.2. Indications
    3.2.2.1. Dysphagia: target population
    3.2.2.2. Other indications
  3.2.3. What to expect?
    3.2.3.1. Customized dosage forms
      3.2.3.1.1. Color
      3.2.3.1.2. Flavor
      3.2.3.1.3. Shape
      3.2.3.1.4. Personalized medications
    3.2.3.2. Release of complex drugs
  3.2.4. 3D drug printing technologies
    3.2.4.1. Inkjet printing
    3.2.4.2. Direct-write
    3.2.4.3. Zip dose
    3.2.4.4. Thermal inkjet (TIJ) printing
    3.2.4.5. Fused deposition modelling (FDM)
    3.2.4.6. Powder bed printing
    3.2.4.7. Stereolithography (SLA)
3.3. MARKET DYNAMICS
  3.3.1. Drivers
    3.3.1.1. High demand of instantaneous soluble tablets
    3.3.1.2. Increasing prevalence of dysphagia
    3.3.1.3. Growing usage of 3D printing
    3.3.1.4. Increasing adoption of personalized drugs
  3.3.2. Restraints
    3.3.2.1. 3D printing could be used to print illegal drugs
    3.3.2.2. Stringent government regulations for 3D printed products
  3.3.3. Opportunities
    3.3.3.1. Growing healthcare infrastructure and increase in healthcare investment in emerging nations
    3.3.3.2. Rising awareness about the 3D printing technology
  3.3.4. Impact analysis

CHAPTER 4 SPRITAM: 3D PRINTED DRUGS MARKET

4.1. OVERVIEW
  4.1.1. Key market trends
  4.1.2. Growth factors and opportunities
4.2. MARKET SIZE AND FORECAST
4.3. BY GEOGRAPHY
  4.3.1. U.S.
    4.3.1.1. Key market trends
    4.3.1.2. Growth factors and opportunities
    4.3.1.3. Market size and forecast
  4.3.2. Rest of World
    4.3.2.1. Growth factors and opportunities
    4.3.2.2. Market size and forecast

CHAPTER 5 OTHER 3D PRINTED DRUGS POTENTIAL MARKET, BY SCENARIO

5.1. OVERVIEW
  5.1.1. Market size and forecast
5.2. LOW GROWTH SCENARIO
  5.2.1. Market size and forecast
5.3. MODERATE GROWTH SCENARIO
  5.3.1. Market size and forecast
5.4. HIGH GROWTH SCENARIO
  5.4.1. Market size and forecast

CHAPTER 6 OTHER 3D PRINTED DRUGS POTENTIAL MARKET, BY REGION

6.1. OVERVIEW
6.2. NORTH AMERICA
  6.2.1. Key market trends
  6.2.2. Key growth factors and opportunities
  6.2.3. Market size and forecast
  6.2.4. U.S.
  6.2.5. Rest of North America
6.3. EUROPE
  6.3.1. Key market trends
  6.3.2. Key growth factors and opportunities
  6.3.3. Market size and forecast
  6.3.4. UK
  6.3.5. Germany
  6.3.6. France
  6.3.7. Italy
  6.3.8. Spain
  6.3.9. Rest of Europe
6.4. ASIA-PACIFIC
  6.4.1. Key market trends
  6.4.2. Key growth factors and opportunities
  6.4.3. Market size and forecast
  6.4.4. Japan
  6.4.5. China
  6.4.6. Australia
  6.4.7. Rest of Asia-Pacific
6.5. LAMEA
  6.5.1. Key market trends
  6.5.2. Key growth factors and opportunities
  6.5.3. Market size and forecast
  6.5.4. Brazil
  6.5.5. Saudi Arabia
  6.5.6. Rest of LAMEA

CHAPTER 7 COMPANY PROFILES

7.1. APRECIA PHARMACEUTICALS COMPANY
  7.1.1. Company overview
  7.1.2. Company snapshot
  7.1.3. Operating business segments
  7.1.4. Key strategic moves and developments
7.2. FABRX LTD.
  7.2.1. Company overview
  7.2.2. Company snapshot
  7.2.3. Operating business segments
7.3. GLAXOSMITHKLINE PLC
  7.3.1. Company overview
  7.3.2. Company snapshot
  7.3.3. Operating business segments
  7.3.4. Business performance

List Of Tables

LIST OF TABLES

TABLE 1. LIST OF 3D PRINTED DRUGS DEVELOPED BY APRECIA PHARMACEUTICALS APPROVED BY FDA
TABLE 2. GLOBAL 3D PRINTED DRUGS MARKET FOR SPRITAM, BY GEOGRAPHY, 2017-2023 ($MILLION)
TABLE 3. OTHER 3D PRINTED DRUGS POTENTIAL MARKET, BY SCENARIO, 2020-2030 ($MILLION)
TABLE 4. OTHER 3D PRINTED DRUGS POTENTIAL MARKET, BY LOW GROWTH SCENARIO, BY REGION, 2020-2030, ($MILLION)
TABLE 5. OTHER 3D PRINTED DRUGS POTENTIAL MARKET, BY MODERATE GROWTH SCENARIO, BY REGION, 2020-2030, ($MILLION)
TABLE 6. OTHER 3D PRINTED DRUGS POTENTIAL MARKET, BY HIGH GROWTH SCENARIO, BY REGION, 2020-2030, ($MILLION)
TABLE 7. NORTH AMERICA OTHER 3D PRINTED DRUGS POTENTIAL MARKET, LOW GROWTH SCENARIO, BY COUNTRY, 2020-2030, ($MILLION)
TABLE 8. NORTH AMERICA OTHER 3D PRINTED DRUGS POTENTIAL MARKET, MODERATE GROWTH SCENARIO, BY COUNTRY, 2020-2030, ($MILLION)
TABLE 9. NORTH AMERICA OTHER 3D PRINTED DRUGS POTENTIAL MARKET, RAPID GROWTH SCENARIO, BY COUNTRY, 2020-2030, ($MILLION)
TABLE 10. EUROPE OTHER 3D PRINTED DRUGS POTENTIAL MARKET, LOW GROWTH SCENARIO, BY COUNTRY, 2020-2030, ($MILLION)
TABLE 11. EUROPE OTHER 3D PRINTED DRUGS POTENTIAL MARKET, MODERATE GROWTH SCENARIO, BY COUNTRY, 2020-2030, ($MILLION)
TABLE 12. EUROPE OTHER 3D PRINTED DRUGS POTENTIAL MARKET, RAPID GROWTH SCENARIO, BY COUNTRY, 2020-2030, ($MILLION)
TABLE 13. ASIA-PACIFIC OTHER 3D PRINTED DRUGS POTENTIAL MARKET, LOW GROWTH SCENARIO, BY COUNTRY, 2020-2030, ($MILLION)
TABLE 14. ASIA-PACIFIC OTHER 3D PRINTED DRUGS POTENTIAL MARKET, MODERATE GROWTH SCENARIO, BY COUNTRY, 2020-2030, ($MILLION)
TABLE 15. ASIA-PACIFIC OTHER 3D PRINTED DRUGS POTENTIAL MARKET, RAPID GROWTH SCENARIO, BY COUNTRY, 2020-2030, ($MILLION)
TABLE 16. LAMEA OTHER 3D PRINTED DRUGS POTENTIAL MARKET, LOW GROWTH SCENARIO, BY COUNTRY, 2020-2030, ($MILLION)
TABLE 17. LAMEA OTHER 3D PRINTED DRUGS POTENTIAL MARKET, MODERATE GROWTH SCENARIO, BY COUNTRY, 2020-2030, ($MILLION)
TABLE 18. LAMEA OTHER 3D PRINTED DRUGS POTENTIAL MARKET, HIGH GROWTH SCENARIO, BY COUNTRY, 2020-2030, ($MILLION)
TABLE 19. APRECIA PHARMACEUTICALS: COMPANY SNAPSHOT
TABLE 20. APRECIA PHARMACEUTICALS: OPERATING SEGMENT
TABLE 21. FABRX: COMPANY SNAPSHOT
TABLE 22. FABRX: PRODUCT SEGMENT
TABLE 23. GSK: COMPANY SNAPSHOT
TABLE 24. GSK: OPERATING SEGMENTS

List Of Figures

LIST OF FIGURES

FIGURE 1. PREVALENCE OF DYSPHAGIA ASSOCIATED WITH VARIOUS DIORDERS, 2008 (IN PERCENTAGE)
FIGURE 2. IMPACT ANALYSIS, 2017
FIGURE 3. U.S. 3D PRINTED DRUGS MARKET FOR SPRITAM, 2017-2023 ($MILLION)
FIGURE 4. REST OF WORLD 3D PRINTED DRUGS MARKET FOR SPRITAM, 2017-2023 ($MILLION)
FIGURE 5. OTHER 3D PRINTED DRUGS POTENTIAL MARKET, BY LOW GROWTH SCENARIO, 2020-2030 ($MILLION)
FIGURE 6. OTHER 3D PRINTED DRUGS POTENTIAL MARKET, BY MODERATE GROWTH SCENARIO, 2020-2030 ($MILLION)
FIGURE 7. OTHER 3D PRINTED DRUGS POTENTIAL MARKET, BY HIGH GROWTH SCENARIO, 2020-2030 ($MILLION)
FIGURE 8. OTHER 3D PRINTED DRUGS POTENTIAL MARKET, SHARE BY REGION, 2020 (%)
FIGURE 9. U.S. OTHER 3D PRINTED DRUGS POTENTIAL MARKET, LOW GROWTH SCENARIO, 2020-2030 ($MILLION)
FIGURE 10. U.S. OTHER 3D PRINTED DRUGS POTENTIAL MARKET, MODERATE GROWTH SCENARIO, 2020-2030 ($MILLION)
FIGURE 11. U.S. OTHER 3D PRINTED DRUGS POTENTIAL MARKET, RAPID GROWTH SCENARIO, 2020-2030 ($MILLION)
FIGURE 12. REST OF NORTH AMERICA OTHER 3D PRINTED DRUGS POTENTIAL MARKET, LOW GROWTH SCENARIO, 2020-2030 ($MILLION)
FIGURE 13. REST OF NORTH AMERICA OTHER 3D PRINTED DRUGS POTENTIAL MARKET, MODERATE GROWTH SCENARIO, 2020-2030 ($MILLION)
FIGURE 14. REST OF NORTH AMERICA OTHER 3D PRINTED DRUGS POTENTIAL MARKET, RAPID GROWTH SCENARIO, 2020-2030 ($MILLION)
FIGURE 15. UK OTHER 3D PRINTED DRUGS POTENTIAL MARKET, LOW GROWTH SCENARIO, 2020-2030 ($MILLION)
FIGURE 16. UK OTHER 3D PRINTED DRUGS POTENTIAL MARKET, MODERATE GROWTH SCENARIO, 2020-2030 ($MILLION)
FIGURE 17. UK OTHER 3D PRINTED DRUGS POTENTIAL MARKET, RAPID GROWTH SCENARIO, 2020-2030 ($MILLION)
FIGURE 18. GERMANY OTHER 3D PRINTED DRUGS POTENTIAL MARKET, LOW GROWTH SCENARIO, 2020-2030 ($MILLION)
FIGURE 19. GERMANY OTHER 3D PRINTED DRUGS POTENTIAL MARKET, MODERATE GROWTH SCENARIO, 2020-2030 ($MILLION)
FIGURE 20. GERMANY OTHER 3D PRINTED DRUGS POTENTIAL MARKET, RAPID GROWTH SCENARIO, 2020-2030 ($MILLION)
FIGURE 21. FRANCE OTHER 3D PRINTED DRUGS POTENTIAL MARKET, LOW GROWTH SCENARIO, 2020-2030 ($MILLION)
FIGURE 22. FRANCE OTHER 3D PRINTED DRUGS POTENTIAL MARKET, MODERATE GROWTH SCENARIO, 2020-2030 ($MILLION)
FIGURE 23. FRANCE OTHER 3D PRINTED DRUGS POTENTIAL MARKET, RAPID GROWTH SCENARIO, 2020-2030 ($MILLION)
FIGURE 24. ITALY OTHER 3D PRINTED DRUGS POTENTIAL MARKET, LOW GROWTH SCENARIO, 2020-2030 ($MILLION)
FIGURE 25. ITALY OTHER 3D PRINTED DRUGS POTENTIAL MARKET, MODERATE GROWTH SCENARIO, 2020-2030 ($MILLION)
FIGURE 26. ITALY OTHER 3D PRINTED DRUGS POTENTIAL MARKET, RAPID GROWTH SCENARIO, 2020-2030 ($MILLION)
FIGURE 27. SPAIN OTHER 3D PRINTED DRUGS POTENTIAL MARKET, LOW GROWTH SCENARIO, 2020-2030 ($MILLION)
FIGURE 28. SPAIN OTHER 3D PRINTED DRUGS POTENTIAL MARKET, MODERATE GROWTH SCENARIO, 2020-2030 ($MILLION)
FIGURE 29. SPAIN OTHER 3D PRINTED DRUGS POTENTIAL MARKET, RAPID GROWTH SCENARIO, 2020-2030 ($MILLION)
FIGURE 30. REST OF EUROPE OTHER 3D PRINTED DRUGS POTENTIAL MARKET, LOW GROWTH SCENARIO, 2020-2030 ($MILLION)
FIGURE 31. REST OF EUROPE OTHER 3D PRINTED DRUGS POTENTIAL MARKET, MODERATE GROWTH SCENARIO, 2020-2030 ($MILLION)
FIGURE 32. REST OF EUROPE OTHER 3D PRINTED DRUGS POTENTIAL MARKET, RAPID GROWTH SCENARIO, 2020-2030 ($MILLION)
FIGURE 33. JAPAN OTHER 3D PRINTED DRUGS POTENTIAL MARKET, LOW GROWTH SCENARIO, 2020-2030 ($MILLION)
FIGURE 34. JAPAN OTHER 3D PRINTED DRUGS POTENTIAL MARKET, MODERATE GROWTH SCENARIO, 2020-2030 ($MILLION)
FIGURE 35. JAPAN OTHER 3D PRINTED DRUGS POTENTIAL MARKET, RAPID GROWTH SCENARIO, 2020-2030 ($MILLION)
FIGURE 36. CHINA OTHER 3D PRINTED DRUGS POTENTIAL MARKET, LOW GROWTH SCENARIO, 2020-2030 ($MILLION)
FIGURE 37. CHINA OTHER 3D PRINTED DRUGS POTENTIAL MARKET, MODERATE GROWTH SCENARIO, 2020-2030 ($MILLION)
FIGURE 38. CHINA OTHER 3D PRINTED DRUGS POTENTIAL MARKET, RAPID GROWTH SCENARIO, 2020-2030 ($MILLION)
FIGURE 39. AUSTRALIA OTHER 3D PRINTED DRUGS POTENTIAL MARKET, LOW GROWTH SCENARIO, 2020-2030 ($MILLION)
FIGURE 40. AUSTRALIA OTHER 3D PRINTED DRUGS POTENTIAL MARKET, MODERATE GROWTH SCENARIO, 2020-2030 ($MILLION)
FIGURE 41. AUSTRALIA OTHER 3D PRINTED DRUGS POTENTIAL MARKET, RAPID GROWTH SCENARIO, 2020-2030 ($MILLION)
FIGURE 42. REST OF ASIA-PACIFIC OTHER 3D PRINTED DRUGS POTENTIAL MARKET, LOW GROWTH SCENARIO, 2020-2030 ($MILLION)
FIGURE 43. REST OF ASIA-PACIFIC OTHER 3D PRINTED DRUGS POTENTIAL MARKET, MODERATE GROWTH SCENARIO, 2020-2030 ($MILLION)
FIGURE 44. REST OF ASIA-PACIFIC OTHER 3D PRINTED DRUGS POTENTIAL MARKET, RAPID GROWTH SCENARIO, 2020-2030 ($MILLION)
FIGURE 45. BRAZIL OTHER 3D PRINTED DRUGS POTENTIAL MARKET, LOW GROWTH SCENARIO, 2020-2030 ($MILLION)
FIGURE 46. BRAZIL OTHER 3D PRINTED DRUGS POTENTIAL MARKET, MODERATE GROWTH SCENARIO, 2020-2030 ($MILLION)
FIGURE 47. BRAZIL OTHER 3D PRINTED DRUGS POTENTIAL MARKET, HIGH GROWTH SCENARIO, 2020-2030 ($MILLION)
FIGURE 48. SAUDI ARABIA OTHER 3D PRINTED DRUGS POTENTIAL MARKET, LOW GROWTH SCENARIO, 2020-2030 ($MILLION)
FIGURE 49. SAUDI ARABIA OTHER 3D PRINTED DRUGS POTENTIAL MARKET, MODERATE GROWTH SCENARIO, 2020-2030 ($MILLION)
FIGURE 50. SAUDI ARABIA OTHER 3D PRINTED DRUGS POTENTIAL MARKET, HIGH GROWTH SCENARIO, 2020-2030 ($MILLION)
FIGURE 51. REST OF LAMEA OTHER 3D PRINTED DRUGS POTENTIAL MARKET, LOW GROWTH SCENARIO, 2020-2030 ($MILLION)
FIGURE 52. REST OF LAMEA OTHER 3D PRINTED DRUGS POTENTIAL MARKET, MODERATE GROWTH SCENARIO, 2020-2030 ($MILLION)
FIGURE 53. REST OF LAMEA OTHER 3D PRINTED DRUGS POTENTIAL MARKET, HIGH GROWTH SCENARIO, 2020-2030 ($MILLION)
FIGURE 54. GSK: REVENUE, 2014-2016 ($MILLION)
FIGURE 55. GSK: REVENUE SHARE BY SEGMENT, 2016 (%)
FIGURE 56. GSK: REVENUE SHARE BY GEOGRAPHY, 2016 (%)